The global orphan drugs market exhibited moderate growth during 2014-2019. Looking forward, IMARC Group expects the global orphan drugs market to exhibit moderate growth during the next five years. To learn more about this market, visit us at: https://www.imarcgroup.com/orphan-drugs-market We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report. The report provides an analysis of the key trends in each sub-segment of the global orphan drugs market report, along with forecasts for growth at the global, regional and country level from 2020-2025. The competitive landscape of the market has also been analyzed in the report with the detailed profiles of the key players. For more information, request for a free sample report here: https://www.imarcgroup.com/orphan-drugs-market/requestsample Contact Us: IMARC Group 30 N Gould St, Ste R Sheridan, WY (Wyoming) 82801 USA Email: Sales@imarcgroup.com Tel No:(D) +91 120 433 0800 Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

1. www.imarcgroup.com Sales@imarcgroup.com +1-631-791-1145
Global Orphan Drugs Market Research Report and Forecast 2020 - 2025

2. About IMARC
WHO WE ARE?
• We are a leading market
research firm with
expertise in market
intelligence and business
research
• We deliver high quality,
well-knitted, meaningful
studies
• We excel at understanding
and synergizing with the
business priorities of our
partners and delivering
tailored solutions
WHAT DO WE DO?
• Market research and
business insights
• Competitive intelligence
and benchmarking
• Strategy consulting
• Consumer surveys and
feedback analysis
• Social and rural research
• Market entry strategy
• Syndicated Reports
WHAT DO WE COVER?
• Food And beverages
• Dairy and dairy products
• Agriculture and farming
• Chemicals and materials
• FMCG
• Paper and packaging
• Healthcare
• Machinery, electronics and
semiconductors
WHO DO WE SERVE?
• Collaborating with fortune
500 companies and SMEs
• Serving all major clients
from different industry
which include Chemical &
Materials, Food &
Beverages, Packaging,
Healthcare, Automotive,
Heavy Industries, Retail,
etc.

3. WhatWeDo
Cost Modeling and Cost Forecasting
Competitive Intelligence and Benchmarking
Country Entry Strategy
Consumer Survey & Feedback Reports
A good cost model supports organizations during negotiations to build strong
relationships with suppliers. Cost modelling and price forecasting services from
IMARC ensure clients make informed decisions.
At IMARC, we help customers determine a competitor’s brand image and
perception in the marketplace as compared to other key players.
IMARC team drafts and implement an optimum country entry strategy for
expanding business in the country. Our team of consultants deeply evaluates
and strategize the market opportunities for our clients and accentuate the
business in congruence with Government regulations, exports and imports
scenario, demand supply gap analysis and many more.
Consumer profiling, survey with end consumers, collection of their feedback
and deep analysis. Based on the analysis, strategic decisions to enter in a
new region, launch of new product, improvising the existing services
Market Research & Business Insights
To develop deep customer understanding, we employ a range of quantitative
and qualitative marketing research approaches along with big data
techniques that are both innovative and pragmatic
Competitive
Intelligence and
Benchmarking
Cost Modeling
and Cost
Forecasting
Country Entry
Strategy
Consumer
Survey &
Feedback
Reports
Market Research
& Business
Insights

4. REPORT OBJECTIVES &
Highlight

5. According to IMARC Group’s latest report, titled “Orphan Drugs Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast
2020-2025,”. Looking forward, IMARC Group expects the global orphan drugs market to exhibit moderate growth during the next five
years.
Orphan drugs are used to diagnose, prevent, and treat rare medical disorders. These drugs aim to meet particular public health
requirements and generally have a limited production, only for a small group of patients. Orphan drugs help in treating several
oncological, metabolic, hematologic, immunologic, infectious, and neurological ailments. These ailments majorly include lymphoma,
leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, etc.
Request for a free sample copy of this report: https://www.imarcgroup.com/orphan-drugs-market/requestsample
Market Trends:
The high prevalence of cancer and other rare genetic disorders is primarily driving the need for orphan drugs. Several pharma companies
are focusing on developing new orphan drugs for providing personalized therapies for patients. Additionally, the higher approval rate of
several pipeline drugs, along with the introduction of numerous favorable government policies to curb the spread of various infectious
diseases, is also catalyzing the market growth. Moreover, extensive R&D activities for the development of biological orphan drugs that can
treat cancer and minimize the damage caused to the stem cells are further expected to drive the market for orphan drugs in the coming
years.
Report Description

6. Orphan Drugs Market 2020-2025 Analysis and Segmentation:
Competitive Landscape:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the
market.
• Some of these key players include:
• AbbVie Inc.
• Alexion Pharmaceuticals Inc.
• Amgen Inc.
• Biogen Inc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche AG (Roche Holding AG)
• Jazz Pharmaceuticals Plc
• Johnson & Johnson
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
Report Description

7. • The report has segmented the market on the basis of drug type, disease type, phase, top selling drug, distribution channel and
region.
• Breakup by Drug Type:
• Biological
• Non-Biological
• Breakup by Disease Type:
• Oncology
• Hematology
• Neurology
• Cardiovascular
• Others
• Breakup by Phase:
• Phase I
• Phase II
• Phase III
• Phase IV
Report Description

8. • Breakup by Top Selling Drugs:
• Revlimid
• Rituxan
• Copaxone
• Opdivo
• Keytruda
• Imbruvica
• Avonex
• Sensipar
• Soliris
• Others
• Breakup by Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Stores
• Others
• Breakup by Region:
• North America
• United States
• Canada
• Asia Pacific
• China
Report Description

9. • Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa
Report Description

10. • Key highlights of the report:
• Market Performance (2014-2019)
• Market Outlook (2020- 2025)
• Porter’s Five Forces Analysis
• Market Drivers and Success Factors
• SWOT Analysis
• Value Chain
• Comprehensive mapping of the competitive landscape
Explore full report with table of contents: https://www.imarcgroup.com/orphan-drugs-market
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the
customization.
Browse Related Report By IMARC Group
Acne Drugs Market: https://www.imarcgroup.com/acne-drugs-market
Regenerative Medicine Market: https://www.imarcgroup.com/regenerative-medicine-market
Report Description

11. Key Questions Answered in This Report:
•How has the global orphan drugs market performed so far and how will it perform in the coming years?
•What has been the impact of COVID-19 on the global orphan drugs market?
•What are the key regional markets?
•What is the breakup of the market based on the drug type?
•What is the breakup of the market based on the disease type?
•What is the breakup of the market based on the phase?
•What is the breakup of the market based on the top selling drugs?
•What is the breakup of the market based on the distribution channel?
•What are the various stages in the value chain of the industry?
•What are the key driving factors and challenges in the industry?
•What is the structure of the global orphan drugs market and who are the key players?
•What is the degree of competition in the industry?
Report Description

12. Table of Contents

13. 1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Orphan Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Type
6.1 Biological
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Non-Biological
6.2.1 Market Trends
Table of Contents

14. 7 6.2.2 Market Forecast
7 Market Breakup by Disease Type
7.1 Oncology
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Hematology
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Neurology
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Cardiovascular
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Others
7.5.1 Market Trends
7.5.2 Market Forecast
8 Market Breakup by Phase
8.1 Phase I
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Phase II
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Phase III
Table of Contents

15. 8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Phase IV
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Top Selling Drugs
9.1 Revlimid
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Rituxan
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Copaxone
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Opdivo
9.4.1 Market Trends
9.4.2 Market Forecast
9.5 Keytruda
9.5.1 Market Trends
9.5.2 Market Forecast
9.6 Imbruvica
9.6.1 Market Trends
9.6.2 Market Forecast
9.7 Avonex
9.7.1 Market Trends
Table of Contents

16. 9.7.2 Market Forecast
9.8 Sensipar
9.8.1 Market Trends
9.8.2 Market Forecast
9.9 Soliris
9.9.1 Market Trends
9.9.2 Market Forecast
9.10 Others
9.10.1 Market Trends
9.10.2 Market Forecast
10 Market Breakup by Distribution Channel
10.1 Hospital Pharmacy
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Retail Pharmacy
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Online Stores
10.3.1 Market Trends
10.3.2 Market Forecast
10.4 Others
10.4.1 Market Trends
10.4.2 Market Forecast
11 Market Breakup by Region
11.1 North America
11.1.1 United States
Table of Contents

17. 11.1.1.1 Market Trends
11.1.1.2 Market Forecast
11.1.2 Canada
11.1.2.1 Market Trends
11.1.2.2 Market Forecast
11.2 Asia Pacific
11.2.1 China
11.2.1.1 Market Trends
11.2.1.2 Market Forecast
11.2.2 Japan
11.2.2.1 Market Trends
11.2.2.2 Market Forecast
11.2.3 India
11.2.3.1 Market Trends
11.2.3.2 Market Forecast
11.2.4 South Korea
11.2.4.1 Market Trends
11.2.4.2 Market Forecast
11.2.5 Australia
11.2.5.1 Market Trends
11.2.5.2 Market Forecast
11.2.6 Indonesia
11.2.6.1 Market Trends
11.2.6.2 Market Forecast
11.2.7 Others
11.2.7.1 Market Trends
Table of Contents

18. 11.2.7.2 Market Forecast
11.3 Europe
11.3.1 Germany
11.3.1.1 Market Trends
11.3.1.2 Market Forecast
11.3.2 France
11.3.2.1 Market Trends
11.3.2.2 Market Forecast
11.3.3 United Kingdom
11.3.3.1 Market Trends
11.3.3.2 Market Forecast
11.3.4 Italy
11.3.4.1 Market Trends
11.3.4.2 Market Forecast
11.3.5 Spain
11.3.5.1 Market Trends
11.3.5.2 Market Forecast
11.3.6 Russia
11.3.6.1 Market Trends
11.3.6.2 Market Forecast
11.3.7 Others
11.3.7.1 Market Trends
11.3.7.2 Market Forecast
11.4 Latin America
11.4.1 Brazil
11.4.1.1 Market Trends
Table of Contents

19. 11.4.1.2 Market Forecast
11.4.2 Mexico
11.4.2.1 Market Trends
11.4.2.2 Market Forecast
11.4.3 Others
11.4.3.1 Market Trends
11.4.3.2 Market Forecast
11.5 Middle East and Africa
11.5.1 Market Trends
11.5.2 Market Breakup by Country
11.5.3 Market Forecast
12 SWOT Analysis
12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats
13 Value Chain Analysis
14 Porters Five Forces Analysis
14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes
15 Price Analysis
Table of Contents

20. 16 Competitive Landscape
16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
16.3.1 AbbVie Inc.
16.3.1.1 Company Overview
16.3.1.2 Product Portfolio
16.3.1.3 Financials
16.3.1.4 SWOT Analysis
16.3.2 Alexion Pharmaceuticals Inc.
16.3.2.1 Company Overview
16.3.2.2 Product Portfolio
16.3.2.3 Financials
16.3.2.4 SWOT Analysis
16.3.3 Amgen Inc.
16.3.2.1 Company Overview
16.3.2.2 Product Portfolio
16.3.2.3 Financials
16.3.2.4 SWOT Analysis
16.3.4 Biogen Inc.
16.3.4.1 Company Overview
16.3.4.2 Product Portfolio
16.3.4.3 Financials
16.3.4.4 SWOT Analysis
16.3.5 Bristol Myers Squibb Company
16.3.5.1 Company Overview
Table of Contents

21. 16.3.5.2 Product Portfolio
16.3.5.3 Financials
16.3.5.4 SWOT Analysis
16.3.6 F. Hoffmann-La Roche AG (Roche Holding AG)
16.3.6.1 Company Overview
16.3.6.2 Product Portfolio
16.3.6.3 SWOT Analysis
16.3.7 Jazz Pharmaceuticals Plc
16.3.7.1 Company Overview
16.3.7.2 Product Portfolio
16.3.7.3 Financials
16.3.7.4 SWOT Analysis
16.3.8 Johnson & Johnson
16.3.8.1 Company Overview
16.3.8.2 Product Portfolio
16.3.8.3 Financials
16.3.8.4 SWOT Analysis
16.3.9 Merck & Co. Inc.
16.3.9.1 Company Overview
16.3.9.2 Product Portfolio
16.3.9.3 Financials
16.3.9.4 SWOT Analysis
16.3.10 Novartis AG
16.3.10.1 Company Overview
16.3.10.2 Product Portfolio
16.3.10.3 Financials
Table of Contents

22. 16.3.10.4 SWOT Analysis
16.3.11 Pfizer Inc.
16.3.11.1 Company Overview
16.3.11.2 Product Portfolio
16.3.11.3 Financials
16.3.11.4 SWOT Analysis
16.3.12 Sanofi S.A.
16.3.12.1 Company Overview
16.3.12.2 Product Portfolio
16.3.12.3 Financials
16.3.12.4 SWOT Analysis
16.3.13 Takeda Pharmaceutical Company Limited
16.3.13.1 Company Overview
16.3.13.2 Product Portfolio
16.3.13.3 Financials
16.3.13.4 SWOT Analysis
16.3.14 Teva Pharmaceutical Industries Ltd
16.3.14.1 Company Overview
16.3.14.2 Product Portfolio
16.3.14.3 Financials
16.3.14.4 SWOT Analysis
Table of Contents

23. Report FAQs
Team ProfileTeam Profile

24. Team Profile
Engineers
45%
Post
Graduates
30%
Non
Engineering
Graduates
15%
Others
10%
Growing team of 150+ employees with
deep market knowledge
Over 1000 Independent Consultants from
different sectors
Talents from some of the top universities
modelling specialists with unmatched
expertise in quantitative research
Individuals with experience in specific
industries and having sound knowledge of
targeted functional areas
Commercial and non-commercial
relationships with some of the top research
institutes
Engineers and Post Graduates Account for
75% of our Team

25. Report FAQs
Words From Client

26. “We have been working with IMARC Group for over two years now. I must say that the word impossible
doesn’t seems to appear in their dictionary,. These guys can provide data for any market in any country. I
have been given them challenging assignments to work upon and have been quite impressed with their
approach and results.” -Global
Procurement Technology Manager – Global FMCG Giant
“IMARC Group has great domain expertise and knowledge base provided all the inputs necessary for us to
define the path forward and launch our diagnostic successfully in the market where other players were always
afraid before investing.”
-Vice President Marketing – European Diagnostic Company
“We were really impressed with their research findings on the South India dairy market. The innovative idea
suggested by them have given us altogether different aspect to look at the problem. We started with them on
small project but now thinking on doing more strategic project with them.”
-National Manager (Marketing) – Indian Diary Giant
“IMARC Group helped us with the outsourcing of a major part of clinical trials to India. In the beginning we
were skeptic of this idea. But the success achieved from this strategy is driving us to outsource other verticals
of our business to low cost destinations”
- Member of Board of Managing Director – Global Pharmaceutical Giant
“Working with IMARC Group has been a great experience. They were able to provide us with a comprehensive
business report on the India wastewater treatment market. The finding from the reports are played a major
role in our business strategies and future decision making”
-Senior Vice President – Major Indian Effluent Treatment Company
Words From Client

27. Report FAQs
Report FAQs

28. Report FAQs
01
04
Do you provide market share information for a specific
country/segment?
Yes, we provide market share information and insights considering the scope. This service is
provided as a part of customization requirements.
I have a pre-defined budget. Can I buy chapters/sections of the report?
We generally do not promote the sale of separate or individual segments from within a study, as it
might fail to relay the actual meaning of the study or provide a holistic picture of the market. However,
in special cases, select chapters are provided based on the client requirement.
02
My research requirement is very specific; can I customized the report?
Yes, we provide customization of reports based on your requirements. It will be charged based on the scope
of customization. Client have free access to pre-sales analyst briefs to discuss requirement and
recommendations.
03
How do you arrive at the market numbers?
Our research methodology is a three cyclic process. It starts from information procurement from our
inhouse database, primary research and secondary sources. The second step is data collection and
analysis. The third step is data validation from industry experts, key players and other stakeholders.
05
Do you offer post sales support?
Yes, we offer post purchase analyst support for 4-6 weeks to our client in case they have any query within
the scope of study.

29. Report FAQs
08
06 Who are your client?
We have engaged 550+ clients across the globe. More than half of our client are re-engage us for
additional reports and services
07 How will I receive the report?
The report in a PDF and Excel format will be sent to you electronically at your registered email address.
Moreover, PPT and Word formats are also delivered to clients, on special requests.
09
How often does IMARC update studies?
Research studies or reports are updated once in 6 months or a year depending on the traction & need. Please
contact our sales team to inquire about a report update status.
Will I have to pay for the post-sale customization needs?
We offer our clients with a free 10% customization on the syndicated report. In case you have not availed this
service as a pre-sale facility, we request you to share the requirements with our sales team. The research team
post a feasibility will share the purview of the post-sale customization along with the price (if applicable) and
the timeline.

30. SOME OF OUR KEY CUSTOMERS